Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 17 Apr 2014 |
| Articles of Association for Genmab A/S | 15 Apr 2014 |
| Passing of Genmab A/S’ Annual General Meeting | 9 Apr 2014 |
| Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees | 9 Apr 2014 |
| Genmab’s Total Number of Voting Rights and Total Share Capital | 31 Mar 2014 |
| Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen | 26 Mar 2014 |